Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neurogene Inc.
Report date March 31, 2023 · Filed April 04, 2023
Section 16 reporting ended · disclosed 2023-04-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,313 |
Ending reported balance
After 2023-04-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-31 · Exercise / conversion · Acquired 10,000 · Balance 41,082 Row 2 · 2023-04-03 · Sale · Disposed 3,769 · Balance 37,313 F1: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $0.6831 and the highest price at which shares were sold was $0.6980. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2023-03-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-31 · Exercise / conversion · Disposed 10,000 · Balance 0 F3: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4: The RSUs vested as to 1/2 of the total number of shares underlying the award on April 30, 2022 and the remainder of the RSUs vested on March 31, 2023 pursuant to an agreement between the Reporting Person and the Issuer. F5: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $0.6831 and the highest price at which shares were sold was $0.6980. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F4: The RSUs vested as to 1/2 of the total number of shares underlying the award on April 30, 2022 and the remainder of the RSUs vested on March 31, 2023 pursuant to an agreement between the Reporting Person and the Issuer.
F5: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2023 Filed Apr 4, 2023 20:51 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 3,769 | $0.69 | $2,607.77 |
DisclosureSEC source: 0001209191-23-023100 · doc4.xml · nonDerivative · entry 2 Patel Priti · CIK 0001859997 · Former Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,313 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $0.6831 and the highest price at which shares were sold was $0.6980. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:51 UTC | Neurogene Inc. NLTX · Entity 5160 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023100 · doc4.xml · derivative · entry 3 Patel Priti · CIK 0001859997 · Former Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vested as to 1/2 of the total number of shares underlying the award on April 30, 2022 and the remainder of the RSUs vested on March 31, 2023 pursuant to an agreement between the Reporting Person and the Issuer. F5 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:51 UTC | Neurogene Inc. NLTX · Entity 5160 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023100 · doc4.xml · nonDerivative · entry 1 Patel Priti · CIK 0001859997 · Former Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 16:32 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 14,380 | $0.60 | $8,587.74 |
DisclosureSEC source: 0001209191-23-006881 · doc4.xml · nonDerivative · entry 2 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,082 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $0.576 and the highest price at which shares were sold was $0.635. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Includes 2,000 shares of Common Stock acquired by the Reporting Person on May 13, 2022 and 2,000 shares of Common Stock acquired by the Reporting Person on November 15, 2022 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:32 UTC | Neurogene Inc. NLTX · Entity 5160 | Exercise / conversionRestricted Stock Units · Derivative | 35,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006881 · doc4.xml · derivative · entry 3 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 16:32 UTC | Neurogene Inc. NLTX · Entity 5160 | Exercise / conversionCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006881 · doc4.xml · nonDerivative · entry 1 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,000 shares of Common Stock acquired by the Reporting Person on May 13, 2022 and 2,000 shares of Common Stock acquired by the Reporting Person on November 15, 2022 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 16:40 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-22-044433 · doc4.xml · derivative · entry 1 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-08-01 F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 2, 2023, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 02, 2022 Filed May 3, 2022 19:16 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 5,538 | $1.22 | $6,748.61 |
DisclosureSEC source: 0001209191-22-026894 · doc4.xml · nonDerivative · entry 2 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,462 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $1.21 and the highest price at which shares were sold was $1.25. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein. F1 · balance_after: Includes 2,000 shares of common stock acquired by the Reporting Person on November 15, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| April 30, 2022 Filed May 3, 2022 19:16 UTC | Neurogene Inc. NLTX · Entity 5160 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026894 · doc4.xml · derivative · entry 3 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F5 · derivative.exercise_date: The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F6 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. Read SEC document |
| April 30, 2022 Filed May 3, 2022 19:16 UTC | Neurogene Inc. NLTX · Entity 5160 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026894 · doc4.xml · nonDerivative · entry 1 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,000 shares of common stock acquired by the Reporting Person on November 15, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 16:39 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantRestricted Stock Units · Derivative | 70,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006395 · doc4.xml · derivative · entry 1 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 16:23 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-049928 · doc4.xml · derivative · entry 1 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-08-03 F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 3, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 30, 2021 Filed May 4, 2021 16:35 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $12.49 | $0.00 |
DisclosureSEC source: 0001209191-21-029907 · doc4.xml · derivative · entry 2 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2031-04-30 F4 · derivative.exercise_date: The option vests as to 1/4 of the total shares on April 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 30, 2021 Filed May 4, 2021 16:35 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029907 · doc4.xml · derivative · entry 1 Patel Priti · CIK 0001859997 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.